Delcath Begins Platform Expansion With Two Phase 2 Trials
Portfolio Pulse from
Delcath Systems is expanding its platform with two Phase 2 trials, funded by $25 million from Tranche B Warrants. Q3 US sales reached $10 million, and the HEPZATO KIT hospital rollout is progressing. Delcath aims to have 15 centers by year-end and 30 by 2025.
November 20, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Delcath Systems' Q3 US sales reached $10 million, unlocking $25 million from Tranche B Warrants to fund Phase 2 trials. The HEPZATO KIT rollout is progressing, with plans to expand to 30 centers by 2025.
The $10 million in Q3 sales and the unlocking of $25 million in funding are positive indicators for Delcath's financial health and growth prospects. The successful rollout of HEPZATO KIT and expansion plans suggest strong future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100